EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Sugentech Inc (253840) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Sugentech Inc KRW 2,223, price KRW 4,565, upside -51.3%, quality 46 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR · ISIN KR7253840003

SI Thin data Sep 24, 2026

Sugentech Inc

253840 · KQ

Weakest SetupStrongly overvalued and low quality.

!Fair value 2,223 KRW · Strongly overvalued (−51%)
!Quality 46/100
!Weak Growth (revenue 5y −25.6 %/yr)
!Low debt · negative free cash flow
!Trails peers (1/7)
!Narrow moat 9/100
!Evidence only low, so the estimate is less certain
Watch Sugentech Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

31,631 KRW 3,620 KRW Fair Value 2,223 KRW Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 3,620 KRW – 31,631 KRW · fair‑value band 1,467 KRW – 2,779 KRW · the 4,565 KRW price screens above the 2,223 KRW fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Sugentech in your weekly email

Every Wednesday you see whether Sugentech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sugentech Inc. develops and sells in-vitro diagnostic systems and products based on biotechnology, information technology, and nanotechnology in South Korea and internationally. The company offers lab tests, including systems and test items; and COVID-19 tests.

Show more

Sugentech Inc. develops and sells in-vitro diagnostic systems and products based on biotechnology, information technology, and nanotechnology in South Korea and internationally. The company offers lab tests, including systems and test items; and COVID-19 tests. It also provides point of care testing analyzers and test items for testing of influenza A/B, antibody test, COVID-19 and flu, SARS-CoV-2, HbA1c, beta-hcg, YSH, T3/T4, and CRP; and digital health and home tests, including mobile health, ovulation, and pregnancy products. The company was formerly known as Accugen Healthcare, Inc. and changed its name to Sugentech Inc. in October 2013. Sugentech Inc. was founded in 2011 and is headquartered in Daejeon, South Korea.

Stock analysis

Sugentech Inc (253840) currently trades at 4,565 KRW, while our model-based Fair Value estimate is 2,223 KRW, implying the stock looks roughly 105.4% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the evidence level at low.

Scenario range: 1,467 KRW (bear) to 2,779 KRW (bull), the price of 4,565 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Sugentech Inc reported revenue of 9.4B KRW in FY2025 versus 77.2B KRW in FY2021, a compound −40.9%/yr. Reported net income was −23.3B KRW in FY2025.

Key figures

Market cap 69.8B KRW (≈ $51.3M) · P/S ratio 6.18 · Net margin −248% · Return on equity −29.5% · Return on assets (EBIT) −4.8% · Operating margin −200% · Revenue (TTM) 9.9B KRW · Revenue growth (YoY) +24.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades about 41% below its 52-week high and 26% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −51%, 253840 screens richer than that median.

Fair Value models

Bear 1,467 KRW Fair Value 2,223 KRW Bull 2,779 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 2,495 KRW 3,344 KRW 4,991 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 2,495 KRW 3,344 KRW 4,991 KRW 54

Open the full fair value analysis →

Notify me when 253840 reaches fair value

Put 253840 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 46/100

Of which business quality 44 · Market factors (momentum, volatility) 28

Profitability 0
Margins and returns on capital today
Quality Growth 38
Are margins and returns improving?
Cashflow 3
Earnings quality: real cash, not paper profit
Fin. Strength 76
Balance sheet, leverage, solvency risk
Investment 96
Disciplined investing over empire-building
Low Volatility 47
Calm price path (market factor)
Momentum 26
Price trend over the last 3–12 months (market factor)
52W Momentum 12
Distance to the 52-week high (market factor)
Net Issuance 90
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−6.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−54.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−25.6%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
71.5% (2020) → −199.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

253840 screens 105% overvalued. Compare with Abbott Laboratories, →

Compare Sugentech Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 44 · Below median
Fair Value upside −51% · Below median
Profitability
Return on assets −12% · Bottom 25%
Operating margin (TTM) −200% · Bottom 25%
Growth and dividend
Revenue growth 24% · Top 25%
Balance sheet
Debt / equity 0.14× · Above median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 10
FUTURE (revenue growth)100 · sector 31
PAST (return on equity)0 · sector 7
HEALTH (low debt)93 · sector 97
DIVIDEND (yield)0 · sector 40

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $103.49 $74.79 −28%
Stryker Corporation SYK $273.40 $300.74 +10%
Medtronic plc MDT $89.30 $65.57 −27%
Boston Scientific Corporation BSX $44.62 $49.08 +10%
Edwards Lifesciences Corporation EW $86.82 $82.04 −6%
Siemens Healthineers AG SHL €37.21 €35.22 −5%
DexCom, Inc DXCM $87.73 $96.50 +10%
GE HealthCare Technologies Inc GEHC $66.27 $69.62 +5%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥156.68 ¥172.35 +10%
Koninklijke Philips N.V PHIA €21.85 €15.32 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sugentech Inc · Fair Value
2,223 KRW −105%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Sugentech Inc Fair Value". https://www.fairvalue-calculator.com/stock/253840

Frequently asked questions

Is Sugentech Inc (253840) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 2,223 KRW versus a price of 4,565 KRW, about −51% upside (overvalued).
What is the fair value of 253840?
Our model-based fair value for Sugentech Inc is 2,223 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 4,565 KRW.
What is the quality score of 253840?
Sugentech Inc has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sugentech Inc (253840)?
Our model-based price target is the fair value of 2,223 KRW (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 1,467 KRW, optimistic scenario 2,779 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Sugentech Inc stock forecast for 2026?
Our models put fair value at 2,223 KRW, about −51% upside versus a price of 4,565 KRW (overvalued). Cautious scenario 1,467 KRW, optimistic scenario 2,779 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Sugentech Inc (253840)?
Sugentech Inc reported trailing-twelve-month revenue of about 9.9B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Sugentech Inc (253840)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sugentech Inc it is 2,223 KRW per share (as of Sep 24, 2026), against a price of 4,565 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Sugentech Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 253840 trades above its calculated fair value: price 4,565 KRW, fair value 2,223 KRW, a gap of about −51% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 253840?
No. The price is what the market pays today (4,565 KRW); the fair value is what the company's own numbers justify (2,223 KRW). For Sugentech Inc the two are 2,342 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Sugentech Inc worth?
The market values Sugentech Inc at about 69.8B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 4,565 KRW; our models calculate a fair value of 2,223 KRW per share.
What do the bullish and bearish scenarios say about 253840?
Our models span a range for Sugentech Inc: cautious scenario 1,467 KRW, base 2,223 KRW, optimistic 2,779 KRW per share (as of Sep 24, 2026, price 4,565 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sugentech Inc (253840)?
Balance-sheet figures for Sugentech Inc (as of Sep 24, 2026): return on equity −29.5%, debt of 0.14 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is 253840 from its 52-week high?
Sugentech Inc trades at 4,565 KRW, about 41% below its 52-week high of 7,700 KRW and 26% above the low of 3,620 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 2,223 KRW is for.
Which stocks are comparable to Sugentech Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sugentech Inc stock attractive at the current price?
The data as of Sep 24, 2026: price 4,565 KRW, calculated fair value 2,223 KRW (−51%), Quality Score 46/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 253840 calculated?
We run Sugentech Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 2,223 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Sugentech Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sugentech Inc (253840)?
The closing price on Sep 23, 2026 was 4,565 KRW. Our model-based fair value is 2,223 KRW, about −51% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sugentech Inc right now?
The price sits above even our optimistic bull case (2,779 KRW). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (1,467 KRW to 2,779 KRW) leaves room in how you read the outcome.

Key figures of Sugentech Inc

How large is the market capitalisation of Sugentech Inc (253840)?
The market capitalisation of Sugentech Inc is 69.8B KRW (≈ $51.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sugentech Inc (253840)?
The price-to-sales ratio of Sugentech Inc is 6.18 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Sugentech Inc (253840)?
The net margin of Sugentech Inc is −248% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sugentech Inc (253840)?
The return on equity (ROE) of Sugentech Inc is −29.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sugentech Inc (253840)?
On an EBIT basis the return on assets of Sugentech Inc is −4.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sugentech Inc (253840)?
The operating margin of Sugentech Inc is −200% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sugentech Inc (253840)?
Revenue at Sugentech Inc is growing +24.2% versus a year earlier (3y avg −54.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sugentech Inc (253840)?
Earnings per share at Sugentech Inc are growing −84.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Sugentech Inc (253840) generate?
The free cash flow of Sugentech Inc is −15.0B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Sugentech Inc (253840) carry?
The net debt of Sugentech Inc is 6.0B KRW (fiscal year 2019). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Sugentech Inc in the live analysis

One click puts Sugentech Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.